Skip to main content

Steqeyma News

Celltrion Announces U.S. FDA Approval of Additional Presentation of Steqeyma (ustekinumab-stba), Expanding Dosing Options for Pediatric Patients

INCHEON, South Korea, June 15, 2025  -- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new presentation of Steqeyma® (ustekinumab-stba), a biosimilar t...

FDA Approves Steqeyma (ustekinumab-stba), a Biosimilar to Stelara

JERSEY CITY, N.J., Dec. 17, 2024 – Celltrion announced today that the U.S. Food and Drug Administration (FDA) has approved Steqeyma (ustekinumab-stba), a biosimilar to Stelara (ustekinumab), for...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Crohn's Disease, Crohn's Disease - Acute, Psoriasis, Plaque Psoriasis, Psoriatic Arthritis, Ulcerative Colitis, Ulcerative Colitis - Active

Steqeyma patient information at Drugs.com